Passage Bio to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company specializing in neurodegenerative diseases, has announced its participation in two major upcoming investor conferences.

The company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025, at 9:10 a.m. ET, and the Leerink Global Biopharma Conference in Miami on March 12, 2025, at 8:00 a.m. ET. Both events will feature management presentations and investor meetings.

Interested parties can access live webcasts of the presentations through the Investors & Media section of Passage Bio's website at investors.passagebio.com. Replay recordings will remain available for 30 days after each event.

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:

TD Cowen 45^th Annual Health Care Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 5, 2025
Presentation Time: 9:10 a.m. ET
Location: Boston, MA

Leerink Global Biopharma Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 12, 2025
Presentation Time: 8:00 a.m. ET
Location: Miami, FL

A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. 

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com

FAQ

When and where will Passage Bio (PASG) present at the TD Cowen Healthcare Conference 2025?

Passage Bio will present at the TD Cowen Healthcare Conference in Boston on March 5, 2025, at 9:10 a.m. ET.

What is the schedule for PASG's presentation at the Leerink Global Biopharma Conference 2025?

Passage Bio will present at the Leerink Conference in Miami on March 12, 2025, at 8:00 a.m. ET.

How can investors access Passage Bio's (PASG) conference presentations?

Investors can access live webcasts through Passage Bio's website at investors.passagebio.com, with replays available for 30 days after each event.

What type of meetings will Passage Bio (PASG) conduct at these conferences?

Passage Bio management will participate in both presentations and investor meetings at both conferences.